Nivolumab

The addition of nivolumab to first-line chemotherapy significantly improved PFS, but not OS, for patients with advanced or recurrent HER2-negative gastric and gastroesophageal junction cancer, according to phase 3 study findings.

Adjuvant nivolumab significantly prolonged DFS compared with placebo for patients with high-risk, muscle-invasive urothelial carcinoma, according to topline data released by the agent’s manufacturer.

A “sandwich” approach to melanoma treatment consisting of immunotherapy between two targeted therapy courses showed a trend toward improved total PFS, according to study results presented at ESMO Virtual Congress 2020.

Nivolumab plus chemotherapy increased PFS and OS compared with chemotherapy alone among previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, study results showed.

Nivolumab plus cabozantinib conferred superior PFS, OS and response rates compared with sunitinib as a first-line treatment for advanced renal cell carcinoma, according to results of a phase 3 study presented at ESMO Virtual Congress 2020.

Among patients with hepatocellular carcinoma who first failed Retevmo, Stivarga and Opdivo provided similar outcomes in terms of survival as second-line treatments, according to research presented at The Digital International Liver Congress.

Nivolumab plus ipilimumab- and pembrolizumab-based therapies may be the most cost-effective approaches in advanced melanoma, according to a study.

First-line nivolumab plus ipilimumab significantly extended OS compared with platinum-based chemotherapy for patients with unresectable malignant pleural mesothelioma, according to results of an interim analysis of the CheckMate 743 trial.

Cancer can be a very personal and individualized disease, with predictable and unpredictable outcomes.

The FDA approved four regimens for non-small cell lung cancer since mid-May.